Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal

EpimAb Biotherapeutics sold global rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in a $635 million deal. Meanwhile, Shenzhen TargetRx raised $20 million by selling China commercial rights for an ALK inhibitor to Simcere.